Current application of exhaled nitric oxide in clinical practice - 09/11/16
Doi : 10.1016/j.jaci.2016.09.002
Joseph D. Spahn, MD a, Jonathan Malka, MD b, Stanley J. Szefler, MD c, ⁎ 
a Allergy and Immunology Department, Children's Hospital Colorado, Aurora, Colo
c The Breathing Institute, Pulmonary Department, Children's Hospital Colorado, Aurora, Colo
b Pediatric Associates, Lauderdale Lakes, Fla
∗Corresponding author: Stanley J. Szefler, MD, Children's Hospital Colorado, 13123 E 16th Avenue, Aurora, CO 80045.Children's Hospital Colorado13123 E 16th AvenueAuroraCO80045
Key words : Asthma, childhood asthma, dupilumab, inhaled corticosteroids, lebrikizumab, nitric oxide, mepolizumab, omalizumab, severe asthma
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. Malka has received payment for lectures and travel support from Aerocrine and Mead Johnson. S. J. Szefler has consultant arrangements with Roche, AstraZeneca, Aerocrine, Daiichi Sankyo, Boehringer Ingelheim, Merck, Genentech, and Novartis and has received grants from GlaxoSmithKline. J. D. Spahn declares that he has no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 138 - N° 5
P. 1296-1298 - novembre 2016 Retour au numéro
Article précédent
- Exercise-induced bronchoconstriction update—2016
- John M. Weiler, John D. Brannan, Christopher C. Randolph, Teal S. Hallstrand, Jonathan Parsons, William Silvers, William Storms, Joanna Zeiger, David I. Bernstein, Joann Blessing-Moore, Matthew Greenhawt, David Khan, David Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Diane E. Schuller, Stephen A. Tilles, Dana Wallace
- The Editors' Choice
- Cezmi A. Akdis, Zuhair K. Ballas, Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?